Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.

Hypoxia-mediated mitochondria apoptosis inhibition induces temozolomide treatment resistance through miR-26a/Bad/Bax axis.
复制标题

缺氧介导的线粒体凋亡抑制通过 miR-26a/Bad/Bax 轴诱导替莫唑胺治疗耐药

DOI:
10.1038/s41419-018-1176-7
复制
发表时间:
2018-11-13
影响因子:
9
通讯作者:
Jiang BH
Jiang BH
中科院分区:
生物学1区
文献类型:
--
作者:
Ge X;Pan MH;Wang L;Li W;Jiang C;He J;Abouzid K;Liu LZ;Shi Z;Jiang BH

文献摘要

参考文献

被引文献

相似文献

多形性胶质母细胞瘤(GBM)是中枢神经系统最缺氧的肿瘤之一。尽管替莫唑胺(TMZ)是治疗胶质瘤的有效药物,但缺氧微环境仍是胶质瘤化疗耐药的主要障碍,其机制尚不清楚。本研究发现缺氧可通过HIF-1α介导的miR-26 a上调诱导对TMZ的保护性反应,这与TMZ的体外和体内耐药有关。此外,我们证明HIF-1α/miR-26 a轴通过预防GBM中线粒体功能障碍中的Bax和Bad来加强TMZ抗性的获得。此外,miR-26 a表达水平与Bax、Bad水平和GBM进展呈负相关;但与临床癌症组织中的HIF-1α水平高度相关。这些发现为了解胶质瘤缺氧微环境下TMZ耐药性的机制提供了新的联系,因此HIF-1α/miR-26 a/Bax/Bad信号通路作为TMZ GBM的有希望的辅助治疗。
Glioblastoma multiforme (GBM) is one of the most hypoxic tumors of the central nervous system. Although temozolomide (TMZ) is an effective clinical agent in the GBM therapy, the hypoxic microenvironment remains a major barrier in glioma chemotherapy resistance, and the underlying mechanisms are poorly understood. Here, we find hypoxia can induce the protective response to mitochondrion via HIF-1α-mediated miR-26a upregulation which is associated with TMZ resistance in vitro and in vivo. Further, we demonstrated that HIF-1α/miR-26a axis strengthened the acquisition of TMZ resistance through prevention of Bax and Bad in mitochondria dysfunction in GBM. In addition, miR-26a expression levels negatively correlate with Bax, Bad levels, and GBM progression; but highly correlate with HIF-1α levels in clinical cancer tissues. These findings provide a new link in the mechanistic understanding of TMZ resistance under glioma hypoxia microenvironment, and consequently HIF-1α/miR-26a/Bax/Bad signaling pathway as a promising adjuvant therapy for GBM with TMZ.
DOI: 10.15698/mic2016.12.547
发表时间: 2016-12-05
期刊: Microbial cell (Graz, Austria)
影响因子: --
作者:
Garenne D;Renault TT;Manon S
通讯作者: Manon S
DOI: 10.1021/acs.molpharmaceut.5b00694
发表时间: 2015-12-01
影响因子: 4.9
作者:
Ananta, Jeyarama S.;Paulmurugan, Ramasamy;Massoud, Tank F.
通讯作者: Massoud, Tank F.
DOI: 10.1016/j.neuropharm.2013.05.002
发表时间: 2013-12-01
期刊: NEUROPHARMACOLOGY
影响因子: 4.7
作者:
Gielen, Paul R.;Aftab, Qurratulain;Sin, Wun Chey
通讯作者: Sin, Wun Chey
DOI: 10.2174/157488710790820544
发表时间: 2010-01-01
影响因子: 1.9
作者:
Quick, Allison;Patel, Disha;Mehta, Minesh
通讯作者: Mehta, Minesh
DOI: 10.1128/mcb.00945-09
发表时间: 2009-11-01
影响因子: 5.3
作者:
Martorell, Lluis;Gentile, Maurizio;Martinez-Gonzalez, Jose
通讯作者: Martinez-Gonzalez, Jose